(Q51892517)

17 April 2018

title

Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments. (English)

1 reference

17 April 2018

author

Mark Bower

6

1 reference

17 April 2018

author name string

Justin Stebbing

1

1 reference

17 April 2018

Christopher Wood

2

1 reference

17 April 2018

Michael Atkins

3

1 reference

17 April 2018

Ronald Bukowski

4

1 reference

17 April 2018

Stephen Litwin

5

1 reference

17 April 2018

Andrew Parsa

7

1 reference

17 April 2018

Hyam Levitsky

8

1 reference

17 April 2018

language of work or name

English

0 references

publication date

1 March 2008

1 reference

17 April 2018

published in

Cancer

1 reference

17 April 2018

volume

112

1 reference

17 April 2018

issue

5

1 reference

17 April 2018

page(s)

955-961

1 reference

17 April 2018

HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic m

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Generation of tumor-specific cytotoxic T lymphocytes and memory T cells by immunization with tumor-derived heat shock protein gp96.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Enhancement of Cancer Radiation Therapy by Use of Adenovirus-Mediated Secretable Glucose-Regulated Protein 94/gp96 Expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine interleukin 12

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Genetic immunotherapy by intrapleural, intraperitoneal and subcutaneous injection of IL-2 gene-modified Lewis lung carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirus-enhanced transferrinfection (AVET)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Interleukin-2 gene therapy of surgical minimal residual tumour disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Preparation of murine B7.1-glycosylphosphatidylinositol and transmembrane-anchored staphylococcal enterotoxin. A dual-anchored tumor cell vaccine and its antitumor effect

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Anti-metastatic activity of hapten-modified autologous tumor cell vaccine in an animal tumor model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Therapy of spontaneous metastases with an autologous tumor vaccine in a guinea pig model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Active specific immunotherapy of established micrometastasis: effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Effect of perioperative chemoimmunotherapy with cyclophosphamide and autologous tumor vaccine in murine MBT-2 bladder cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Inducing long-term survival with lasting anti-tumor immunity in treating B cell lymphoma by a combined dendritic cell-based and hydrodynamic plasmid-encoding IL-12 gene therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Enhanced antitumoral effectiveness of idiotype vaccination induced by the administration of Flt3 ligand combined with interleukin 2 against a murine myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Clinical results of vaccine therapy for cancer: learning from history for improving the future

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

A clinical development paradigm for cancer vaccines and related biologics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23273

7 January 2021

Identifiers

DOI

10.1002/CNCR.23273

1 reference

17 April 2018

1 reference

17 April 2018